Advertisement

Neurochemical Research

, Volume 37, Issue 2, pp 401–409 | Cite as

Pericyte-derived Glial Cell Line-derived Neurotrophic Factor Increase the Expression of Claudin-5 in the Blood–brain Barrier and the Blood-nerve Barrier

  • Fumitaka Shimizu
  • Yasuteru Sano
  • Kazuyuki Saito
  • Masa-aki Abe
  • Toshihiko Maeda
  • Hiroyo Haruki
  • Takashi Kanda
Original Paper

Abstract

The destruction of blood–brain barrier (BBB) and blood-nerve barrier (BNB) has been considered to be a key step in the disease process of a number of neurological disorders including cerebral ischemia, Alzheimer’s disease, multiple sclerosis, and diabetic neuropathy. Although glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) facilitate neuronal or axonal regeneration in the brain or peripheral nerves, their action in the BBB and BNB remains unclear. The purpose of the present study was to elucidate whether these neurotrophic factors secreted from the brain or peripheral nerve pericytes increase the barrier function of the BBB or BNB, using our newly established human brain microvascular endothelial cell (BMEC) line or peripheral nerve microvascular endothelial cell (PnMEC) line. GDNF increased the expression of claudin-5 and the transendothelial electrical resistance (TEER) of BMECs and PnMECs, whereas BDNF did not have this effect. Furthermore, we herein demonstrate that the GDNF secreted from the brain and peripheral nerve pericytes was one of the key molecules responsible for the up-regulation of claudin-5 expression and the TEER value in the BBB and BNB. These results indicate that the regulation of GDNF secreted from pericytes may therefore be a novel therapeutic strategy to modify the BBB or BNB functions and promote brain or peripheral nerve regeneration.

Keywords

GDNF Blood–brain barrier Blood-nerve barrier Pericytes Endothelial cells 

Notes

Acknowledgments

This work was supported by research grants (Nos. 22790821 and Nos. 21390268) from the Japan Society for the Promotion of Science, Tokyo, Japan and also by research grant (K2002528) from Health and Labor Sciences Research Grants for research on intractable diseases (Neuroimmunological Disease Research Committee) from the Ministry of Health, Labor and Welfare of Japan.

Conflict of interest

The authors declare that there is no duality of interest associated with this manuscript.

References

  1. 1.
    Poduslo JF, Curran GL, Berg CT (1994) Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 91:5705–5709PubMedCrossRefGoogle Scholar
  2. 2.
    Engelhardt B (2010) T cell migration into the central nervous system during health and disease: Different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol 1:79–93CrossRefGoogle Scholar
  3. 3.
    Sano Y, Shimizu F, Nakayama H et al (2008) Endothelial cells constituting blood-nerve barrier have highly specialized characteristics as barrier-forming cells. Cell Struct Funct 32:139–147CrossRefGoogle Scholar
  4. 4.
    Hori S, Ohtsuki S, Hosoya K et al (2004) A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 89:503–513PubMedCrossRefGoogle Scholar
  5. 5.
    Kim JH, Kim JH, Park JA et al (2006) Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 39:339–345PubMedCrossRefGoogle Scholar
  6. 6.
    Shimizu F, Sano Y, Maeda T et al (2008) Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol 217:388–399PubMedCrossRefGoogle Scholar
  7. 7.
    Shimizu F, Sano Y, Abe MA et al (2011) Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol 226:255–266PubMedCrossRefGoogle Scholar
  8. 8.
    Sariola H, Saarma M (2003) Novel functions and signalling pathways for GDNF. J Cell Sci 116:3855–3862PubMedCrossRefGoogle Scholar
  9. 9.
    Gill SS, Patel NK, Hotton GR et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589–595PubMedCrossRefGoogle Scholar
  10. 10.
    Sherer TB, Fiske BK, Svendsen CN et al (2006) Crossroads in GDNF therapy for Parkinson’s disease. Mov Disord 21:136–141PubMedCrossRefGoogle Scholar
  11. 11.
    Wang LJ, Lu YY, Muramatsu S et al (2002) Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 22:6920–6928PubMedGoogle Scholar
  12. 12.
    Klein SM, Behrstock S, McHugh J et al (2005) GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 16:509–521PubMedCrossRefGoogle Scholar
  13. 13.
    Boyd JG, Gordon T (2003) Glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor sustain the axonal regeneration of chronically axotomized motoneurons in vivo. Exp Neurol 183:610–619PubMedCrossRefGoogle Scholar
  14. 14.
    Mizuta I, Ohta M, Ohta K et al (2001) Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 310:117–120PubMedCrossRefGoogle Scholar
  15. 15.
    Wang Y, Chang CF, Morales M et al (2002) Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury. Ann NY Acad Sci 962:423–437PubMedCrossRefGoogle Scholar
  16. 16.
    Bruno V, Battaglia G, Copani A et al (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013–1033PubMedCrossRefGoogle Scholar
  17. 17.
    Utsumi H, Chiba H, Kamimura Y et al (2000) Expression of GFRalpha-1, receptor for GDNF, in rat brain capillary during postnatal development of the BBB. Am J Physiol Cell Physiol 279:361–368Google Scholar
  18. 18.
    Igarashi Y, Chiba H, Utsumi H et al (2000) Expression of receptors for glial cell line-derived neurotrophic factor (GDNF) and neurturin in the inner blood-retinal barrier of rats. Cell Struct Funct 25:237–241PubMedCrossRefGoogle Scholar
  19. 19.
    Sano Y, Shimizu F, Abe M et al (2010) Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 225:519–528PubMedCrossRefGoogle Scholar
  20. 20.
    Kashiwamura Y, Sano Y, Abe M et al (2011) Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem Res 36:849–855PubMedCrossRefGoogle Scholar
  21. 21.
    Varley CL, Garthwaite MA, Cross W et al (2006) PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol 208:407–417PubMedCrossRefGoogle Scholar
  22. 22.
    Ghassemifar MR, Eckert JJ, Houghton FD et al (2003) Gene expression regulating epithelial intercellular junction biogenesis during human blastocyst development in vitro. Mol Hum Reprod 9:245–252PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang ZL, Liu ZS, Sun Q (2006) Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 12:4241–4245PubMedGoogle Scholar
  24. 24.
    Nitta T, Hata M, Gotoh S et al (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161:653–660PubMedCrossRefGoogle Scholar
  25. 25.
    Ohtsuki S, Yamaguchi H, Katsukura Y et al (2008) mRNA expression levels of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting. J Neurochem 104:147–154PubMedGoogle Scholar
  26. 26.
    Honda M, Nakagawa S, Hayashi K et al (2006) Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5. Cell Mol Neurobiol 26:109–118PubMedCrossRefGoogle Scholar
  27. 27.
    Bendfeldt K, Radojevic V, Kapfhammer J et al (2007) Basic fibroblast growth factor modulates density of blood vessels and preserves tight junctions in organotypic cortical cultures of mice: a new in vitro model of the blood-brain barrier. J Neurosci 27:3260–3267PubMedCrossRefGoogle Scholar
  28. 28.
    Argaw AT, Gurfein BT, Zhang Y et al (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 106:1977–1982PubMedCrossRefGoogle Scholar
  29. 29.
    Nishikiori N, Osanai M, Chiba H et al (2007) Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 56:1333–1340PubMedCrossRefGoogle Scholar
  30. 30.
    Kaur C, Ling EA (2008) Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 5:71–81PubMedCrossRefGoogle Scholar
  31. 31.
    Cirrito JR, Deane R, Fagan AM et al (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285–3290PubMedCrossRefGoogle Scholar
  32. 32.
    Holman DW, Klein RS, Ransohoff RM (2011) The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta 1812:220–230PubMedGoogle Scholar
  33. 33.
    Lach B, Rippstein P, Atack D et al (1993) Immunoelectron microscopic localization of monoclonal IgM antibodies in gammopathy associated with peripheral demyelinative neuropathy. Acta Neuropathol 85:298–307PubMedCrossRefGoogle Scholar
  34. 34.
    Kanda T, Numata Y, Mizusawa H (2004) Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1. J Neurol Neurosurg Psychiatry 75:765–769PubMedCrossRefGoogle Scholar
  35. 35.
    Giannini C, Dyck PJ (1995) Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 37:498–504PubMedCrossRefGoogle Scholar
  36. 36.
    Shimizu F, Sano Y, Haruki H et al (2011) Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and VEGF by pericytes. Diabetologia 54:1517–1526PubMedCrossRefGoogle Scholar
  37. 37.
    Capowski EE, Schneider BL, Ebert AD et al (2007) Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods 163:338–349PubMedCrossRefGoogle Scholar
  38. 38.
    Hovland DN Jr, Boyd RB, Butt MT et al (2007) Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derivedneurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol 35:1013–1029PubMedCrossRefGoogle Scholar
  39. 39.
    Jakobsson J, Lundberg C (2006) Lentiviral vectors for use in the central nervous system. Mol Ther 13:484–493PubMedCrossRefGoogle Scholar
  40. 40.
    Wong LF, Goodhead L, Prat C et al (2006) Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther 17:1–9PubMedCrossRefGoogle Scholar
  41. 41.
    Cunningham LA, Su C (2002) Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson’s disease. Exp Neurol 174:230–242PubMedCrossRefGoogle Scholar
  42. 42.
    Pertusa M, García-Matas S, Mammeri H et al (2008) Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging 29:1366–1379PubMedCrossRefGoogle Scholar
  43. 43.
    Shen LH, Li Y, Chopp M (2010) Astrocytic endogenous glial cell derived neurotrophic factor production is enhanced by bone marrow stromal cell transplantation in the ischemic boundary zone after stroke in adult rats. Glia 58:1074–1081PubMedCrossRefGoogle Scholar
  44. 44.
    Laganiere J, Kells AP, Lai JT et al (2010) An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson’s disease. J Neurosci 30:16469–16474PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Fumitaka Shimizu
    • 1
  • Yasuteru Sano
    • 1
  • Kazuyuki Saito
    • 2
  • Masa-aki Abe
    • 1
  • Toshihiko Maeda
    • 1
  • Hiroyo Haruki
    • 1
  • Takashi Kanda
    • 1
  1. 1.Department of Neurology and Clinical NeuroscienceYamaguchi University Graduate School of MedicineUbeJapan
  2. 2.Department of Neurology and Clinical NeuroscienceTokyo Medical and Dental Graduate School of MedicineTokyoJapan

Personalised recommendations